197 related articles for article (PubMed ID: 27164857)
1. Dysregulation of the epigenetic regulator SETDB1 in liver carcinogenesis-more than one way to skin a cat.
Longerich T
Chin Clin Oncol; 2016 Dec; 5(6):72. PubMed ID: 27164857
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
Wong CM; Wei L; Law CT; Ho DW; Tsang FH; Au SL; Sze KM; Lee JM; Wong CC; Ng IO
Hepatology; 2016 Feb; 63(2):474-87. PubMed ID: 26481868
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma.
Zhang Y; Huang J; Li Q; Chen K; Liang Y; Zhan Z; Ye F; Ni W; Chen L; Ding Y
BMC Cancer; 2018 May; 18(1):539. PubMed ID: 29739365
[TBL] [Abstract][Full Text] [Related]
4. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
Wei L; Chiu DK; Tsang FH; Law CT; Cheng CL; Au SL; Lee JM; Wong CC; Ng IO; Wong CM
J Hepatol; 2017 Oct; 67(4):758-769. PubMed ID: 28532996
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis.
Long XR; He Y; Huang C; Li J
Int J Oncol; 2014 Jun; 44(6):1915-22. PubMed ID: 24714841
[TBL] [Abstract][Full Text] [Related]
6. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
7. Detection of epigenetic aberrations in the development of hepatocellular carcinoma.
Zhang Y
Methods Mol Biol; 2015; 1238():709-31. PubMed ID: 25421688
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.
Kanda M; Sugimoto H; Kodera Y
World J Gastroenterol; 2015 Oct; 21(37):10584-97. PubMed ID: 26457018
[TBL] [Abstract][Full Text] [Related]
9. The Epigenetic Regulation of HCC Metastasis.
Han TS; Ban HS; Hur K; Cho HS
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544763
[TBL] [Abstract][Full Text] [Related]
10. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of SETDB1 as a therapeutic target.
Karanth AV; Maniswami RR; Prashanth S; Govindaraj H; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Mar; 21(3):319-331. PubMed ID: 28076698
[TBL] [Abstract][Full Text] [Related]
12. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1.
Huang J; Wang Y; Guo Y; Sun S
Hepatology; 2010 Jul; 52(1):60-70. PubMed ID: 20578129
[TBL] [Abstract][Full Text] [Related]
13. Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b.
Fan DN; Tsang FH; Tam AH; Au SL; Wong CC; Wei L; Lee JM; He X; Ng IO; Wong CM
Hepatology; 2013 Feb; 57(2):637-47. PubMed ID: 22991213
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.
Khan FS; Ali I; Afridi UK; Ishtiaq M; Mehmood R
Hepatol Int; 2017 Jan; 11(1):45-53. PubMed ID: 27271356
[TBL] [Abstract][Full Text] [Related]
15. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update.
Liu M; Jiang L; Guan XY
Protein Cell; 2014 Sep; 5(9):673-91. PubMed ID: 24916440
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic Mutations.
Nishida N; Kudo M
Dig Dis; 2016; 34(6):708-713. PubMed ID: 27750242
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of miR-362-3p Modulates Proliferation and Anchorage-Independent Growth by Directly Targeting Tob2 in Hepatocellular Carcinoma.
Shen H; Li W; Tian Y; Xu P; Wang H; Zhang J; Li Y
J Cell Biochem; 2015 Aug; 116(8):1563-73. PubMed ID: 25649327
[TBL] [Abstract][Full Text] [Related]
19. A regulatory circuitry comprising TP53,
Chen B; Wang J; Wang J; Wang H; Gu X; Tang L; Feng X
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30054425
[TBL] [Abstract][Full Text] [Related]
20. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.
Wong CM; Ng YL; Lee JM; Wong CC; Cheung OF; Chan CY; Tung EK; Ching YP; Ng IO
Hepatology; 2007 May; 45(5):1129-38. PubMed ID: 17464989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
